Clinical Trial Update: A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer [Phase 2]

View source ↗

Summary

Phase II study evaluating dovitinib (TKI258) in FGFR2-mutated or wild-type advanced/metastatic endometrial cancer; results were posted after completion in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Cancer

Drugs mentioned

• Dovitinib (TKI258) (dovitinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Solid Tumors and Advanced Endometrial Cancer, Endometrial Cancer | Phase 2 | Status: COMPLETED | Results posted: 2015-03-31